Authentification abonné
lvrea
Accueil Tous les numéros Volume 26 / Numéro 1 (Janvier 2017) Méd. Intensive Réa., 26 1 (2017) 75-84 Références
Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 26, Numéro 1, Janvier 2017
Respiratoire
Page(s) 75 - 84
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-016-1252-x
Publié en ligne 11 janvier 2017
  • Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY, (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374: 1639–1651 [CrossRef] [PubMed] [Google Scholar]
  • Créange A, Felten D, Kiesel I, Renard JL, Vespignani H, Béquet D, (1994) Subacute leukoencephalopathy of the rhombencephalon after pituitary radiotherapy. Rev Neurol (Paris) 150: 704–708 [PubMed] [Google Scholar]
  • Lo Y, Shen LJ, Chen WH, Dong YH, Wu FL, (2016) Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis. J Formos Med Assoc Taiwan Yi Zhi 115: 744–751 [CrossRef] [Google Scholar]
  • Richards A, Marshall H, McQuary A, (2011) Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract 17: 372–380 [CrossRef] [PubMed] [Google Scholar]
  • Yeo KK, HaDuong JH, (2016) The use of continuous veno-venous hemodiafiltration in the management of ifosfamide-induced encephalopathy: a case report. J Pediatr Hematol Oncol 38: 489–490 [CrossRef] [PubMed] [Google Scholar]
  • Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant JP, (2010) Influence on Busilvex® pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res 30: 2977–2984 [PubMed] [Google Scholar]
  • Stein AS, O’Donnell MR, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP, Snyder DS, Molina A, Stepan DE, Spielberger R, Somlo G, Margolin KA, Vora N, Lipsett J, Lee J, Niland J, Forman SJ, (1996) In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 14: 2206–2216 [CrossRef] [PubMed] [Google Scholar]
  • Bleyer A, (2007) “Flushing out” cytosine arabinoside from CSF to reverse neurotoxicity. J Pediatr Hematol Oncol 29:274 [CrossRef] [PubMed] [Google Scholar]
  • Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E, (2011) Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol 103: 603–609 [CrossRef] [PubMed] [Google Scholar]
  • Fyfe G, Fisher RI, Rosenberg SA Sznol M, Parkinson DR, Louie AC, (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696 [CrossRef] [PubMed] [Google Scholar]
  • Atkins MB, Lotze MT, Dutcher JP Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA, (1999) High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105–2116 [CrossRef] [PubMed] [Google Scholar]
  • Lerner DM, Stoudemire A, Rosenstein DL, (1999) Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40: 428–435 [CrossRef] [PubMed] [Google Scholar]
  • Merimsky O, Chaitchik S, (1992) Neurotoxicity of interferon-alpha. Anticancer Drugs 3: 567–570 [CrossRef] [PubMed] [Google Scholar]
  • Quarantini LC, Miranda-Scippa A, Parana R, Sampaio AS, Bressan RA, (2007) Acute dystonia after injection of pegylated interferon alpha-2b. Mov Disord 22: 747–748 [CrossRef] [PubMed] [Google Scholar]
  • Yi HJ, Hong KS, Moon N, Chung SS, Lee RA, Kim KH, (2016) Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy. Ann Surg Treat Res 90: 179–182 [CrossRef] [Google Scholar]
  • Koenig H, Patel A, (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23: 155–160 [CrossRef] [PubMed] [Google Scholar]
  • Shimoyama R, Ban T, Miyake K, Isogai N, Ikegaya Y, Kawachi J, Ogino H, Watanabe K, (2014) Early diagnosis of capecitabine-induced acute leukoencephalopathy by using diffusion-weighted MRI. Gan To Kagaku Ryoho 41: 1251–1253 [PubMed] [Google Scholar]
  • Taguchi Y, Takashima S, Tanaka K, (2015) A case of phenytoin intoxication caused by interaction between phenytoin and capecitabine. Brain Nerve Shinkei Kenkyu No Shinpo 67: 213–217 [Google Scholar]
  • Pirzada NA, Ali II, Dafer RM, (2000) Fluorouracil-induced neurotoxicity. Ann Pharmacother 34: 35–38 [CrossRef] [PubMed] [Google Scholar]
  • Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ, (2011) Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant 17: 300–308 [CrossRef] [Google Scholar]
  • Merkel DE, Griffin NL, Kagan-Hallet K, Von Hoff DD, (1986) Central nervous system toxicity with fludarabine. Cancer Treat Rep 70: 1449–1450 [PubMed] [Google Scholar]
  • Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF, (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70: 1225–1228 [PubMed] [Google Scholar]
  • Newton HB, (2012) Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol 105: 903–916 [CrossRef] [PubMed] [Google Scholar]
  • Thust SC, Blanco E, Michalski AJ, Chong WK, Gaze MN, Phipps K, Mankad K, (2014) MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system. J Med Imaging Radiat Oncol 58: 683–690 [CrossRef] [PubMed] [Google Scholar]
  • Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC, (2015) An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 21: 188–193 [CrossRef] [PubMed] [Google Scholar]
  • Buie LW, Epstein SS, Lindley CM, (2007) Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther 29: 1887–1899 [CrossRef] [PubMed] [Google Scholar]
  • Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group, (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 23: 3376–3382 [CrossRef] [PubMed] [Google Scholar]
  • Sathiapalan RK, El-Solh H, (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18: 543–546 [CrossRef] [PubMed] [Google Scholar]
  • Chotsampancharoen T, Sripornsawan P, Wongchanchailert M, (2016) Two fatal cases of accidental intrathecal vincristine administration: learning from death events. Chemotherapy 61: 108–110 [CrossRef] [Google Scholar]
  • Goss P, Stewart AK, Couture F, Klasa R, Glück S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H, (1999) Combined results of two phase II studies of Taxol™ (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma 34: 295–304 [CrossRef] [PubMed] [Google Scholar]
  • Moore-Maxwell CA, Datto MB, Hulette CM, (2004) Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol 17: 241–247 [CrossRef] [PubMed] [Google Scholar]
  • Markman M, (2003) Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2: 597–607 [CrossRef] [PubMed] [Google Scholar]
  • Holman LL, Ren Y, Westin SN, (2015) Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report. BMC Cancer 15:728 [CrossRef] [PubMed] [Google Scholar]
  • Sohlbach K, Heinze S, Shiratori K, Sure U, Pagenstecher A, Neubauer A, (2006) Encephalopathy in a patient after long-term treatment with thalidomide. J Clin Oncol 24: 4942–4944 [CrossRef] [PubMed] [Google Scholar]
  • Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM, (2015) Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 20: 806–811 [CrossRef] [PubMed] [Google Scholar]
  • Helissey C, Chargari C, Lahutte M, Ricard D, Vedrine L, Ceccaldi B, Le Moulec S, (2012) First case of posterior reversible encephalopathy syndrome associated with vinflunine. Invest New Drugs 30: 2032–2034 [CrossRef] [PubMed] [Google Scholar]
  • Psimaras D, Bompaire F, Taillia H, Ricard D, Taillibert S, (2012) Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies. Bull Cancer (Paris) 99: 851–863 [Google Scholar]
  • Kamiya-Matsuoka C, Paker AM, Chi L, Youssef A, Tummala S, Loghin ME, (2016) Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol 128: 75–84 [CrossRef] [PubMed] [Google Scholar]
  • Sharief U, Perry DJ, (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8: 163–165 [CrossRef] [PubMed] [Google Scholar]
  • Verschraegen C, Conrad CA, Hong WK, (1995) Subacute encephalopathic toxicity of cisplatin. Lung Cancer Amst Neth 13: 305–309 [CrossRef] [Google Scholar]
  • Berman IJ, Mann MP, (1980) Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45: 764–766 [CrossRef] [PubMed] [Google Scholar]
  • Song T, Rao Z, Tan Q, Qiu Y, Liu J, Huang Z, Wang X, Lin T, (2016) Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore) 95: e3173 [CrossRef] [PubMed] [Google Scholar]
  • Truong QV, Abraham J, Nagaiah G, Newton M, Veltri L, (2012) Gemcitabine associated with posterior reversible encephalopathy syndrome (PRES): a case report and review of the literature. Clin Adv Hematol Oncol HO 10: 611–613 [Google Scholar]
  • Teh HS, Fadilah SA, Leong CF, (2007) Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J 48: e46–e49 [PubMed] [Google Scholar]
  • LaPorte J, Solh M, Ouanounou S, (2015) Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma. J Oncol Pharm Pract [in press] [Google Scholar]
  • Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, Butler MO, Rogalla P, Mason W, Joshua AM, Hogg D, (2016) Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4: 175–178 [CrossRef] [PubMed] [Google Scholar]
  • Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, Morgan E, Hijiya N, (2016) Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer 63: 723–726 [CrossRef] [PubMed] [Google Scholar]
  • Tzachanis D, Haider M, Papazisis G, (2016) A case of subacute encephalopathy developing after treatment with clofarabine and methotrexate that resolved with corticosteroids. Am J Ther 23: e937–e940 [CrossRef] [PubMed] [Google Scholar]
  • Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE, (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86: 321–327 [CrossRef] [PubMed] [Google Scholar]
  • Lee HC, Mulanovich V, Nieto Y, (2014) Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemia. J Natl Compr Cancer Netw JNCCN 12: 1660–1664; quiz 1664 [CrossRef] [Google Scholar]
  • Antonsson A, Pawlita M, Feltkamp MCW, Bouwes Bavinck JN, Euvrard S, Harwood CA, Naldi L, Nindl I, Proby CM, Neale RE, Waterboer T, (2013) Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients. J Med Virol 85: 327–335 [CrossRef] [PubMed] [Google Scholar]
  • Waggoner J, Martinu T, Palmer SM, (2009) Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 28: 395–398 [CrossRef] [PubMed] [Google Scholar]
  • Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL, (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports Project. Blood 113: 4834–4840 [CrossRef] [Google Scholar]
  • Silverio KA, Patel SA, (2015) Progressive multifocal leukoencephalopathy with negative JC virus PCR following treatment of follicular lymphoma: implications for biologics in the era of targeted cancer therapy. Case Rep Oncol Med 2015:534529 [PubMed] [Google Scholar]
  • Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, Moskowitz AJ, Rook AH, Jalan P, Loren AW, Landsburg D, Coyne T, Tsai D, Raisch DW, Norris LB, Bookstaver PB, Sartor O, Bennett CL, (2014) Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) Project. Cancer 120: 2464–2471 [CrossRef] [PubMed] [Google Scholar]
  • El Amrani M, Aidi S, Amarenco P, (2003) Cerebral ischemic events and anti-cancer therapy. Rev Neurol (Paris) 159: 371–380 [PubMed] [Google Scholar]
  • Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, Bidlingmaier C, Frühwald MC, Heller C, Schmidt W, Pautard B, Nowak-Göttl U, (2010) Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 115: 4999–5004 [CrossRef] [Google Scholar]
  • Izzedine H, Perazella MA, (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66: 857–868 [CrossRef] [PubMed] [Google Scholar]
  • Richmond J, Gilbar P, Abro E, (2013) Gemcitabine-induced thrombotic microangiopathy. Intern Med J 43: 1240–1242 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.